(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology...
Stats | |
---|---|
本日の出来高 | 114 913 |
平均出来高 | 109 219 |
時価総額 | 53.79M |
EPS | $0 ( 2024-03-19 ) |
次の収益日 | ( $0 ) 2024-06-12 |
Last Dividend | $0.0470 ( 1995-06-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.23 |
ATR14 | $0.00300 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-23 | Cannon Kara | Buy | 150 000 | Common Stock |
2024-02-21 | Cannon Kara | Buy | 10 640 | Common Stock |
2024-02-21 | Cannon Kara | Sell | 5 823 | Common Stock |
2024-02-23 | Eckert Patricia | Buy | 75 000 | Stock Option (to acquire shares of Common Stock) |
2024-01-31 | Pully Steven J | Buy | 79 365 | Common Stock |
INSIDER POWER |
---|
88.53 |
Last 85 transactions |
Buy: 4 325 861 | Sell: 177 248 |
ボリューム 相関
Enzo Biochem Inc 相関
10 最も負の相関 | |
---|---|
FPEI | -0.872 |
ASB-PE | -0.868 |
CUBB | -0.868 |
GL | -0.855 |
FLR | -0.852 |
NX | -0.843 |
MBI | -0.836 |
PQDI | -0.832 |
BGSF | -0.832 |
SPNT-PB | -0.825 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Enzo Biochem Inc 相関 - 通貨/商品
Enzo Biochem Inc 財務諸表
Annual | 2023 |
収益: | $31.06M |
総利益: | $11.57M (37.24 %) |
EPS: | $-1.270 |
FY | 2023 |
収益: | $31.06M |
総利益: | $11.57M (37.24 %) |
EPS: | $-1.270 |
FY | 2022 |
収益: | $107.07M |
総利益: | $41.97M (39.20 %) |
EPS: | $-0.460 |
FY | 2021 |
収益: | $117.73M |
総利益: | $53.58M (45.51 %) |
EPS: | $0.160 |
Financial Reports:
No articles found.
Enzo Biochem Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0470 | 1995-06-29 |
Last Dividend | $0.0470 | 1995-06-29 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.0470 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.82 | -- |
Div. Sustainability Score | 5.02 | |
Div.Growth Potential Score | 0.366 | |
Div. Directional Score | 2.69 | -- |
Year | Amount | Yield |
---|---|---|
1995 | $0.0470 | 0.58% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 2.58 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.333 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.545 | 1.500 | 5.06 | 7.59 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.20 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.78 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.58 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0444 | -1.500 | 9.26 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 33.77 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.879 | 2.00 | -0.293 | -0.586 | [0 - 30] |
freeCashFlowPerShareTTM | -0.909 | 2.00 | -0.455 | -0.909 | [0 - 20] |
debtEquityRatioTTM | 0.0621 | -1.500 | 9.75 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -1.203 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.348 | 1.000 | -8.96 | -8.96 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -10.10 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.129 | 0.800 | -2.47 | -1.977 | [0.5 - 2] |
Total Score | 5.02 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 1.605 | 1.000 | 9.94 | 0 | [1 - 100] |
returnOnEquityTTM | 0.545 | 2.50 | 6.82 | 7.59 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.909 | 2.00 | -0.303 | -0.909 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.879 | 2.00 | -0.293 | -0.586 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.00912 | 1.500 | -3.39 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -3.47 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | 0.366 |
Enzo Biochem Inc
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。